- |||||||||| doxycycline / Generic mfg.
Preclinical, Journal: Generation of inducible mitophagy mice. (Pubmed Central) - Dec 22, 2023
To better understand the pathophysiological role of mitophagy, we generated doxycycline-inducible mitophagy mice using a synthetic mitophagy adaptor protein consisting of an outer mitochondrial membrane targeting sequence and an engineered LIR...Unexpectedly, we were unable to confirm the protective effect of mitophagy in these two pathological models. Further titration of the level of mitophagy induction is required to demonstrate the potency of the protective effects of mitophagy in disease models.
- |||||||||| zoliflodacin (ETX0914) / Entasis Therap, Global Antibiotic Research and Development Partnership
Clinical, PK/PD data, Journal, Combination therapy: Pharmacodynamics of zoliflodacin plus doxycycline combination therapy against Neisseria gonorrhoeae in a gonococcal hollow-fiber infection model. (Pubmed Central) - Dec 22, 2023
P3
The first in class zoliflodacin (spiropyrimidinetrione, DNA Gyrase B inhibitor) is a promising novel antimicrobial in late-stage clinical development for gonorrhea treatment, i.e., the phase III randomized controlled clinical trial (ClinicalTrials.gov Identifier: NCT03959527) was recently finalized, and zoliflodacin showed non-inferiority compared to the recommended ceftriaxone plus azithromycin dual therapy...In a previous static in vitro study, it was indicated that doxycycline/tetracycline inhibited the gonococcal killing of zoliflodacin in 6-h time-kill curve analysis...The present study shows the high efficacy of zoliflodacin plus doxycycline combination therapy using a dynamic HFIM that more accurately and comprehensively simulate gonococcal infection and their treatment, i.e., compared to static in vitro models, such as short-time checkerboard experiments or time-kill curve analysis. Based on our dynamic in vitro HFIM work, zoliflodacin plus doxycycline for the treatment of both gonorrhea and chlamydia can be an effective combination.
- |||||||||| doxycycline / Generic mfg.
Journal: Ribosome-targeting antibiotic control NLRP3-mediated inflammation by inhibiting mitochondrial DNA synthesis. (Pubmed Central) - Dec 22, 2023
In addition, in vivo results indicated that doxycycline mitigated NLRP3 inflammasome-dependent inflammation, including lipopolysaccharide-induced systemic inflammation and endometritis. Taken together, the results unveil the antibiotics targeting the mitoribosome have the ability to mitigate NLRP3 inflammasome activation by inhibiting mitochondrial translation and mtDNA synthesis thus opening up new possibilities for the treatment of NLRP3-related diseases.
- |||||||||| doxycycline / Generic mfg.
Enrollment open: A Study of Doxycycline to Treat Chlamydial Infection (clinicaltrials.gov) - Dec 21, 2023
P4, N=664, Recruiting,
Taken together, the results unveil the antibiotics targeting the mitoribosome have the ability to mitigate NLRP3 inflammasome activation by inhibiting mitochondrial translation and mtDNA synthesis thus opening up new possibilities for the treatment of NLRP3-related diseases. Not yet recruiting --> Recruiting
- |||||||||| doxycycline / Generic mfg.
Journal: DNMT1 downregulation as well as its overexpression distinctly affect mostly overlapping genes implicated in schizophrenia, autism spectrum, epilepsy, and bipolar disorders. (Pubmed Central) - Dec 21, 2023
When transcriptome data of Dnmt1 neurons treated with doxycycline that downregulated DNMT1 was used, 3,356 genes (?31%) were dysregulated with a significant proportion involved in pathways similar to those in untreated cells...Among the genes with transcripts returning to normal levels, ribosome assembly/biogenesis was most significant whereas in absence of DNMT1, a new set of 903 genes became dysregulated and are involved in similar pathways as mentioned above. These findings provide support for overexpression of DNMT1 as well as its downregulation as risk factor for the four disorders and that its levels within a tight range are essential for normal neurodevelopment/mental health.
- |||||||||| doxycycline / Generic mfg.
Journal: Novel renal injury markers in dogs with ehrlichiosis. (Pubmed Central) - Dec 18, 2023
EG dogs were treated with doxycycline twice daily for the first 30 days...EG was observed to have higher uCysB values compared to CG (estimated population mean EG: 248 ng/dL vs. CG: 38 ng/dL, P < 0.001). Increases in uCysB and uClust suggest the presence of renal injury and a possible mechanism for the observed predisposition to chronic kidney disease in dogs with ehrlichiosis.
- |||||||||| Preclinical, Review, Journal: Resurgence of syphilis: focusing on emerging clinical strategies and preclinical models. (Pubmed Central) - Dec 18, 2023
Different preclinical models have recently emerged, such as in vitro culture and mouse models, which will lay a solid foundation for clinical treatment and prevention of syphilis. This review aims to provide a comprehensive summary of the most recent syphilis tactics, including detection, drug resistance treatments, vaccine development, and preclinical models in clinical practice.
- |||||||||| trimethoprim/sulfamethoxazole / Generic mfg., doxycycline / Generic mfg.
Review, Journal: Whipple's disease: A rare disease that can be spotted by many doctors. (Pubmed Central) - Dec 18, 2023
If not promptly recognized and treated, central nervous system involvement may develop, which can be fatal. The therapeutic gold standard has not yet been fully established, particularly in cases of recurrent disease, neurological involvement, and an immune reconstitution inflammatory syndrome that may arise following the initiation of antibiotic therapy.
- |||||||||| emricasan (IDN 6556) / Amerimmune
Preclinical, Journal, Monotherapy: An oral caspase inhibitor as monotherapy or with antibiotics eradicates MRSA skin infections in mice. (Pubmed Central) - Dec 18, 2023
Importantly, the efficacy of emricasan against S. aureus was not due to direct antibacterial activity. Collectively, pan-caspase inhibitor emricasan and emricasan plus doxycycline reduced both the lesion size and bacterial burden in vivo, and emricasan is a potential host-directed immunotherapy against MRSA skin infections in a preclinical mouse model.
- |||||||||| doxycycline / Generic mfg.
Journal: Pediatric Primary Cutaneous Marginal Zone Lymphoma Treated With Doxycycline. (Pubmed Central) - Dec 17, 2023
This case supports the use of doxycycline for the treatment of pediatric PCMZL in patients with widespread involvement despite negative Borrelia serology. Multiple low-risk treatment modalities may be used in conjunction to clear disease in pediatric patients.
- |||||||||| tigecycline / Generic mfg.
Journal: Study on the Genome and Mechanism of Tigecycline Resistance of a Clinical Chryseobacterium indologenes Strain. (Pubmed Central) - Dec 17, 2023
Materials and In this study, we report on a comprehensive analysis of the genomic mechanisms underlying tigecycline resistance in a MDR C. indologenes strain (CI3125) that was resistant to tigecycline but sensitive to tetracycline, doxycycline, and minocycline...Rather, we demonstrate that minimum inhibitory concentration values for tigecycline decreased two- to eight-folds in the presence of five different efflux pump inhibitors [1-(1-naphthyl- methyl)-piperazine, phenyl-arginine-?-naphthylamide, verapamil, reserpine, and carbonyl cyanide 3-chlorophenylhydrazone]...While tet(X2) in CI3125 is silent, our findings suggest that it may be horizontally spread through GIs. Hence, our findings have significant implications for the management of C. indologenes infections in clinical settings.
- |||||||||| doxycycline / Generic mfg.
Trial completion date, Trial primary completion date: Doxycycline for Elbow Tendinopathy (clinicaltrials.gov) - Dec 15, 2023
P1, N=25, Active, not recruiting,
Trial completion date: Nov 2026 --> Mar 2026 Trial completion date: Nov 2023 --> Nov 2024 | Trial primary completion date: Nov 2023 --> Nov 2024
- |||||||||| prednisone / Generic mfg., doxycycline / Generic mfg.
Diagnostic approach for Generalized Lymphadenopathy (Room 5 (Sunset Center)) - Dec 13, 2023 - Abstract #WRMC2024WRMC_689;
He was subsequently started on prednisone with symptomatic improvement...This case highlights a unique scenario of prolonged lymphadenopathy, culminating in an acute presentation initially suggestive of infection or malignancy. A collaborative, multidisciplinary approach uncovered supportive evidence for autoimmune and infectious origins, with lack of histologic malignancy confirmation.
- |||||||||| ceftriaxone / Generic mfg., doxycycline / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
EARLY RECOVERY FROM EPSTEIN BARR VIRUS-INDUCED PNEUMONITIS WITH EARLY CORTICOSTEROID ADMINISTRATION IN IMMUNOCOMPETENT ADOLESCENT (Ninth Avenue & Dolores St.) - Dec 13, 2023 - Abstract #WRMC2024WRMC_247;
Proposed mechanisms for acute lung injury in EBV-induced pneumonitis include accumulation of the virus secondary to rapid viral replication, an autoimmune reaction to the underlying infection and/or both. Most cases reports describe patients successfully treated with combinations of antivirals, corticosteroids and/or immunoglobulins.
- |||||||||| Enrollment open, Trial completion date, Trial primary completion date: COPAT: Comparing Oral Versus Parenteral Antimicrobial Therapy (clinicaltrials.gov) - Dec 11, 2023
P4, N=135, Enrolling by invitation,
The nHAp synthesized utilizing WCE showed excellent potential for biomedical application and can be used as a drug delivery agent for antibiotics, such as DOXh. Not yet recruiting --> Enrolling by invitation | Trial completion date: Mar 2024 --> Aug 2024 | Trial primary completion date: Mar 2024 --> Aug 2024
- |||||||||| Lamprene (clofazimine) / Novartis
Preclinical, Journal, Monotherapy: Superior efficacy of combination antibiotic therapy versus monotherapy in a mouse model of Lyme disease. (Pubmed Central) - Dec 11, 2023
However, 4 dual combinations (doxycycline + ceftriaxone, dapsone + rifampicin, dapsone + clofazimine, doxycycline + cefotaxime) and 3 triple combinations (doxycycline + ceftriaxone+ carbomycin, doxycycline + cefotaxime+ loratadine, dapsone+ rifampicin+ clofazimine) eradicated persistent Bb infections. These results suggest that combination therapy should be investigated in preclinical studies for treating human Lyme disease.
- |||||||||| doxycycline / Generic mfg., azithromycin / Generic mfg.
Trial initiation date: PHARC: Rickettsia Clearance Study (clinicaltrials.gov) - Dec 10, 2023
P2/3, N=72, Not yet recruiting,
Therefore, the integration of the smartphone and electrospun film provides a promising and convenient method for real-time identification of DOX in food analysis. Initiation date: Sep 2023 --> Feb 2024
- |||||||||| Nuzyra (omadacycline) / Paratek
Journal: Prostatic abscess due to carbapenem-resistant K. pneumonia: A case report. (Pubmed Central) - Dec 9, 2023
Immunodeficiency and invasive catheter use may be risk factors for PA and opportunistic bacterial infections. The use of omadacycline for the treatment of carbapenem-resistant Klebsiella pneumoniae infections appears to be effective.
- |||||||||| Journal: Comparative Study on the Efficacy of Two Perioperative Chemotherapy Regimens for Lumbar Brucellosis. (Pubmed Central) - Dec 8, 2023
Both groups did not experience significantly different perioperative and postoperative adverse reactions (P>0.05). For lumbar brucellosis spondylitis with neurological injury, quadruple perioperative chemotherapy of rifampicin, doxycycline, levofloxacin and ceftriaxone can significantly reduce perioperative inflammation, and improve low back/leg pain, as well as promoting neurological function recovery in the short term.
- |||||||||| doxycycline / Generic mfg.
Preclinical, Journal, Gene therapy: Sustained Vision Recovery by OSK Gene Therapy in a Mouse Model of Glaucoma. (Pubmed Central) - Dec 7, 2023
In RGCs, transcription from the doxycycline (DOX)-inducible Tet-On AAV system, returned to baseline 4 weeks after DOX withdrawal...Notably, no adverse effects on retinal structure or body weight were observed in glaucomatous mice with OSK continuously expressed for 21 months providing compelling evidence of efficacy and safety. This work highlights the tremendous therapeutic potential of rejuvenating gene therapies using OSK, not only for glaucoma but also for other ocular and systemic injuries and age-related diseases.
- |||||||||| rifampicin / Generic mfg., doxycycline / Generic mfg., gentamicin sulfate / Generic mfg.
Review, Journal: Nano and microparticle drug delivery systems for the treatment of Brucella infections. (Pubmed Central) - Dec 7, 2023
Nano-medicines responding to environmental stimuli allow to maximize drug delivery targeting macropages, thereby boosting treatment efficacy. Several drug delivery nano-technologies, including solid lipid nanoparticles, liposomes, chitosan, niosomes, and their combinations with chitosan sodium alginate can be employed in combination of antibiotics to successfully eradicate Brucellosis infection from patients.
- |||||||||| doxycycline / Generic mfg.
Journal: Oxidative and ER stress by elevated insulin biosynthesis and palmitic acid in insulin-producing cells. (Pubmed Central) - Dec 6, 2023
To investigate the effect of excessive insulin folding on ER luminal hydrogen peroxide (H2O2) generation, ER stress and viability, insulin was expressed glucose-independently by a doxycycline-regulated Tet-On system in insulin-producing RINm5F cells...The inability of ER catalase to counteract these effects suggests that further damaging factors besides H2O2 are involved in cell dysfunction. Finally, reducing the high insulin demand in the initial phase of T2DM may be crucial in preventing further ?-cell damage caused by gluco-/lipotoxicity.
- |||||||||| ceftriaxone / Generic mfg.
Observational data, Retrospective data, Journal: Ceftriaxone Use Evaluation in Western Zone Tigray Hospitals, Ethiopia: A Retrospective Cross-Sectional Study. (Pubmed Central) - Dec 3, 2023
The appropriateness of ceftriaxone use in Kahsay Abera and Mearg hospitals was 247 (61.8%) and 252 (63%), respectively, in which about one-third of patients' charts were not compliant with the standard treatment guidelines of Ethiopia for general hospitals. In Kahsay Abera and Mearg hospitals, the empiric use of ceftriaxone was 262 (65.5%) and 375 (93.8%), respectively.
|
